SK7696A3 - 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use - Google Patents

9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use Download PDF

Info

Publication number
SK7696A3
SK7696A3 SK76-96A SK7696A SK7696A3 SK 7696 A3 SK7696 A3 SK 7696A3 SK 7696 A SK7696 A SK 7696A SK 7696 A3 SK7696 A3 SK 7696A3
Authority
SK
Slovakia
Prior art keywords
group
straight
carbon atoms
branched alkyl
hydrogen atom
Prior art date
Application number
SK76-96A
Other languages
English (en)
Slovak (sk)
Inventor
Ulrich Niewohner
Erwin Bischoff
Helmuth Schutz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SK7696A3 publication Critical patent/SK7696A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SK76-96A 1995-01-19 1996-01-18 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use SK7696A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501480A DE19501480A1 (de) 1995-01-19 1995-01-19 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one

Publications (1)

Publication Number Publication Date
SK7696A3 true SK7696A3 (en) 1996-08-07

Family

ID=7751828

Family Applications (1)

Application Number Title Priority Date Filing Date
SK76-96A SK7696A3 (en) 1995-01-19 1996-01-18 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use

Country Status (30)

Country Link
US (1) US5866571A (ko)
EP (1) EP0722943A1 (ko)
JP (1) JPH08231546A (ko)
KR (1) KR960029335A (ko)
CN (1) CN1138583A (ko)
AR (1) AR002704A1 (ko)
AU (1) AU4097796A (ko)
BG (1) BG61729B1 (ko)
BR (1) BR9600149A (ko)
CA (1) CA2167349A1 (ko)
CO (1) CO4700524A1 (ko)
CZ (1) CZ16896A3 (ko)
DE (1) DE19501480A1 (ko)
EE (1) EE9600020A (ko)
FI (1) FI960226A (ko)
HR (1) HRP960009A2 (ko)
HU (1) HUP9600107A3 (ko)
IL (1) IL116771A (ko)
MA (1) MA23779A1 (ko)
NO (1) NO960221L (ko)
NZ (1) NZ280829A (ko)
PE (1) PE10597A1 (ko)
PL (1) PL312353A1 (ko)
SG (1) SG47379A1 (ko)
SK (1) SK7696A3 (ko)
SV (1) SV1996000004A (ko)
TN (1) TNSN96005A1 (ko)
TR (1) TR199600701A2 (ko)
YU (1) YU2896A (ko)
ZA (1) ZA96399B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6064072A (en) * 1997-05-12 2000-05-16 Cymer, Inc. Plasma focus high energy photon source
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
ES2381862T3 (es) * 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
HU228316B1 (en) * 2001-12-13 2013-03-28 Daiichi Sankyo Company Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
CA2480856A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
HRP960009A2 (en) 1997-12-31
NO960221L (no) 1996-07-22
HUP9600107A3 (en) 1999-06-28
FI960226A0 (fi) 1996-01-17
AR002704A1 (es) 1998-04-29
KR960029335A (ko) 1996-08-17
TNSN96005A1 (en) 2005-03-15
PL312353A1 (en) 1996-07-22
CO4700524A1 (es) 1998-12-29
DE19501480A1 (de) 1996-07-25
MA23779A1 (fr) 1996-10-01
BR9600149A (pt) 1998-01-06
NZ280829A (en) 1998-04-27
CN1138583A (zh) 1996-12-25
BG61729B1 (bg) 1998-04-30
PE10597A1 (es) 1997-06-13
TR199600701A2 (tr) 1996-08-21
CZ16896A3 (en) 1996-08-14
ZA96399B (en) 1996-08-14
HUP9600107A2 (en) 1997-05-28
AU4097796A (en) 1996-07-25
IL116771A0 (en) 1996-05-14
JPH08231546A (ja) 1996-09-10
NO960221D0 (no) 1996-01-18
SV1996000004A (es) 1997-02-19
US5866571A (en) 1999-02-02
YU2896A (sh) 1999-03-04
EP0722943A1 (de) 1996-07-24
FI960226A (fi) 1996-07-20
IL116771A (en) 1999-06-20
HU9600107D0 (en) 1996-03-28
CA2167349A1 (en) 1996-07-20
EE9600020A (et) 1996-08-15
SG47379A1 (en) 1998-04-17
BG100291A (bg) 1996-07-31

Similar Documents

Publication Publication Date Title
SK7796A3 (en) 2,8-disubstituted quinazolines, their manufacturing process, pharmaceutical drug containing these substances and their application
EP1309594B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
AU720305B2 (en) Purin-6-one derivatives
SK7696A3 (en) 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use
SK8096A3 (en) 2,9-disubstituted purin-6-ones, manufacturing process thereof, pharmaceutical agent containing these subtances and their use
CA2176668C (fr) Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US5721267A (en) Chemotherapeutic pyrrolocarbazole derivatives
EP1339719B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
US5962486A (en) Indole derivatives as prodrugs of 5-HT1 -like receptor agonists
EP0682023B1 (en) Imidazopyridine derivatives and process for preparing the same
FR2816619A1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
US5753672A (en) Imidazopyridine derivatives and process for preparing the same
EP0120832A1 (fr) Alkyl-4-indolonaphtyridines et compositions pharmaceutiques les contenant
US6423731B2 (en) Indole derivatives as prodrugs of 5-HT1-like receptor agonists
WO1992012979A1 (en) 2,4-DIOXO-PYRIDO [2,3-d]PYRIMIDINE-3-ACETIC ACIDS AND ESTERS AND SALTS THEREOF
FR2640975A1 (ko)
FR2816941A1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
FR2812878A1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique